Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid

被引:15
|
作者
Santayana, Elena M. [3 ]
Grim, Shellee A. [1 ,3 ]
Janda, William M. [2 ]
Layden, Jennifer E. [1 ]
Lee, Todd. A. [3 ]
Clark, Nina M. [1 ]
机构
[1] Univ Illinois, Dept Internal Med, Infect Dis Sect, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA
[3] Univ Illinois, Dept Pharm Practice, Chicago, IL 60612 USA
关键词
Enterococci; Resistance; Intermediate susceptibility; FAECIUM INFECTION; PRIOR EXPOSURE; EMERGENCE; THERAPY;
D O I
10.1016/j.diagmicrobio.2012.05.025
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A retrospective matched case-control study of hospitalized patients with vancomycin-resistant Enterococcus (VRE) infection with reduced susceptibility to linezolid was performed in order to identify risk factors for this infection and describe patient outcomes. Forty-eight linezolid nonsusceptible VRE cases were identified between January 1, 2000. and September 30. 2008, and compared to 96 controls with linezolid-susceptible VRE, matched based on culture date and anatomic site of infection. Demographic, clinical and microbiological data were Collected. On univariable analysis, risk factors for reduced linezolid susceptibility included allogeneic hematopoietic stem cell transplant and/or solid organ transplant (odds ratio [OR]: 2.63; 95% confidence interval [Cl]: 1.13-6.15; P = 0.025). receipt of immunosuppressive medications (OR: 2.39; 95% Cl: 1.08-5.29; P = 0.032) including corticosteroids (OR: 2.40; 95% Cl: 1.03-5.58; P = 0.042) and noncorticosteroid immunosuppressives (OR: 2.31; 95% Cl: 1.00-5.30; P = 0.049), and receipt of linezolid within 1 year prior to infection (OR: 34,.50, 95% Cl: 4.60-259.02; P < 0.001). On multivariable analysis, only receipt of linezolid within 1 year remained an independent risk factor for reduced linezolid susceptibility (OR: 31.84; 95% Cl: 4.20-241.39; P < 0.001), although most patients with VRE with reduced linezolid susceptibility had not received linezolid in the year prior. Reduced linezolid susceptibility did not impact patient outcomes including clinical or microbiological cure, hospital length of stay, or all-cause mortality. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:39 / 42
页数:4
相关论文
共 50 条
  • [1] Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus
    Greene, Matthew H.
    Harris, Bryan D.
    Nesbitt, Whitney J.
    Watson, Marley L.
    Wright, Patty W.
    Talbot, Thomas R.
    Nelson, George E.
    OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (10):
  • [2] Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
    Gonzales, RD
    Schreckenberger, PC
    Graham, MB
    Kelkar, S
    DenBesten, K
    Quinn, JP
    LANCET, 2001, 357 (9263): : 1179 - 1179
  • [3] Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus
    Pogue, Jason M.
    Paterson, David L.
    Pasculle, A. William
    Potoski, Brian A.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2007, 28 (12): : 1382 - 1388
  • [4] Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium Bacteremia in cancer patients
    Ghanem, G.
    Hachem, R.
    Jiang, Y.
    Chemaly, R. F.
    Raad, I.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2007, 28 (09): : 1054 - 1059
  • [5] Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium
    Pai, MP
    Rodvold, KA
    Schreckenberger, PC
    Gonzales, RD
    Petrolatti, JM
    Quinn, JP
    CLINICAL INFECTIOUS DISEASES, 2002, 35 (10) : 1269 - 1272
  • [6] Vancomycin-Resistant Enterococcus: Risk Factors, Surveillance, Infections, and Treatment
    Mazuski, John E.
    SURGICAL INFECTIONS, 2008, 9 (06) : 567 - 571
  • [7] Linezolid to treat urinary tract infections caused by vancomycin-resistant Enterococcus
    Pontefract, Benjamin Alan
    Rovelsky, Suzette Amy
    Madaras-Kelly, Karl Joseph
    SAGE OPEN MEDICINE, 2020, 8
  • [8] Risk factors and outcomes associated with the carriage of tigecycline- and vancomycin-resistant Enterococcus faecium
    Kessel, Johanna
    Bender, Jennifer
    Werner, Guido
    Griskaitis, Matas
    Herrmann, Eva
    Lehn, Annette
    Serve, Hubert
    Zacharowski, Kai
    Zeuzem, Stefan
    Vehreschild, Maria J. G. T.
    Wichelhaus, Thomas A.
    Kempf, Volkhard A. J.
    Hogardt, Michael
    JOURNAL OF INFECTION, 2021, 82 (02) : 227 - 234
  • [9] Risk Factors and Outcomes for Vancomycin-Resistant Enterococcus Bloodstream Infection in Children
    Haas, Eric J.
    Zaoutis, Theoklis E.
    Prasad, Priya
    Li, Mingyao
    Coffin, Susan E.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 (10): : 1038 - 1042
  • [10] Linezolid in the treatment of intra-abdominal infections caused by vancomycin-resistant enterococcus
    Leach, TS
    Schaser, RJ
    Todd, WM
    Hafkin, B
    Kaja, RW
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 224 - 224